Import Bdpoma 4mg to USA | Ernest Oncology Bulk Pharma Distributor

Bdpoma 4 mg Capsule: Advanced Pomalidomide Therapy for Relapsed Multiple Myeloma

Are you searching for a dependable Bdpoma 4 mg capsule exporter from India? Ernest Oncology, a key division of Ernest Pharmaceutical Pvt. Ltd., is a premier global supplier and bulk distributor of high-intensity oncology therapeutics. We offer a specialized, regulatory-compliant supply chain serving the UK (London), USA, UAE (Abu Dhabi), Australia, and South Africa, ensuring that critical hematological medications are delivered with pharmaceutical-grade integrity and global logistics expertise.

Detailed Product Overview: What is Bdpoma 4 mg? 

Bdpoma 4 mg is an oral targeted therapy containing the active pharmaceutical ingredient Pomalidomide. It is a third-generation Immunomodulatory Imide (IMiD), specifically engineered to be more potent than its predecessors (Thalidomide and Lenalidomide). Bdpoma is primarily used when other treatments have failed, offering a vital line of defense for patients with complex blood cancers.

The 4mg capsule is the maximum therapeutic strength, often used in pulsed dosing cycles to achieve aggressive tumor reduction while managing patient tolerability.

Primary Therapeutic Indications: 

Bdpoma 4 mg is clinically indicated for the following conditions:

• Relapsed and Refractory Multiple Myeloma (RRMM): For adult patients who have received at least two prior therapies, including both Lenalidomide and a Proteasome Inhibitor (such as Bortezomib), and have demonstrated disease progression on or within 60 days of completion of the last therapy.

• Kaposi Sarcoma: In specific clinical settings where patients are HIV-negative or have failed highly active antiretroviral therapy (HAART).

Mechanism of Action: How Bdpoma 4 mg Works: 

Bdpoma 4 mg exerts its anti-cancer effects through a multi-pathway biological approach:

1. Cereblon Binding: Pomalidomide binds directly to the cereblon protein, part of the E3 ubiquitin ligase complex. This triggers the degradation of Ikaros and Aiolos transcription factors, which are essential for the survival of myeloma cells.

2. Direct Cytotoxicity: It induces cell cycle arrest and apoptosis (programmed cell death) in hematopoietic tumor cells.

3. Inhibition of Angiogenesis: It blocks the formation of new blood vessels that tumors need to grow and spread.

4. Immune Enhancement: It stimulates T-cells and Natural Killer (NK) cells, enhancing the body's natural ability to identify and destroy cancerous cells.

Administration and Dosage Guidelines: 

• Route: Oral administration (capsules).

• Standard Cycle: Typically taken once daily for 21 days of a 28-day cycle (21 days on, 7 days off).

• Instructions: Capsules must be swallowed whole with water. Never break, chew, or open the capsules.

• Timing: It is best taken at the same time each day, with or without food.

• Critical Safety Warning: Embryo-Fetal Toxicity. Like all IMiDs, Bdpoma can cause severe birth defects. Distribution is strictly managed under REMS (Risk Evaluation and Mitigation Strategy) protocols globally.

Why Source Bdpoma 4 mg from Ernest Oncology?

• Verified Exporter from India: Direct access to GMP-certified manufacturing, ensuring 100% authenticity and competitive bulk pricing.

• Logistics Mastery: Expertise in international shipping to the UK, London, USA, Abu Dhabi, Australia, and South Africa, including full documentation and customs support.

• Bulk Supply Stability: We maintain a consistent inventory of 1 mg, 2 mg, and 4 mg strengths to ensure treatment cycles remain uninterrupted.

• B2B Focus: We specialize in supplying international pharmaceutical wholesalers, oncology hospitals, and government health tenders.